Last reviewed · How we verify
Aripiprazole 8-week group
Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.
Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Aripiprazole 8-week group |
|---|---|
| Also known as | Abilify® |
| Sponsor | Seoul National University Hospital |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2/D3 receptor (partial agonist); serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization rather than pure antagonism. This mechanism reduces excessive dopamine signaling in hyperactive pathways while maintaining adequate dopamine function in hypoactive pathways. It also has activity at serotonin 5-HT1A and 5-HT7 receptors, contributing to its efficacy in treating schizophrenia, bipolar disorder, and depression.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute manic or mixed episodes)
- Major depressive disorder (adjunctive treatment)
- Irritability associated with autism spectrum disorder
Common side effects
- Akathisia
- Headache
- Anxiety
- Insomnia
- Nausea
- Weight gain
- Tremor
- Sedation
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (NA)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression (PHASE3)
- Psychoeducational Group for Depression (NA)
- Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study
- Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole 8-week group CI brief — competitive landscape report
- Aripiprazole 8-week group updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI